Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Post-Prostatectomy Radiotherapy
NCT03388619Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2018
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial in prostate cancer (PCa) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose (MTD) of Radiation Dose to Prostate Bed and Dose to Tumor Reported in Gray (Gy) at 3 weeks and Maximum Tolerated Dose (MTD) of Radiation Dose to Prostate Bed and Dose to Tumor Reported in Fractions at 3 weeks. Started Jan 2018; status: completed.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03388619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03388619.